Brought to you by 
Altacor gets R&D rights to Proximagen's PRX00933 for glaucoma
03 Jan 2012
Executive Summary
Altacor Ltd. (ocular surface disease, ocular infections, and glaucoma) will co-develop Proximagen Group PLC’s (mainly neurology and oncology therapeutics) PRX00933 for glaucoma. Altacor gets the option for exclusive global rights to all ophthalmic indications while Proximagen retains rights in all other therapeutic areas.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Altacor gets R&D rights to Proximagen's PRX00933 for glaucoma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice